Publications

Found 2668 results
Filters: First Letter Of Last Name is S  [Clear All Filters]
2022
Sanchez, A. M., Jacewicz, A., and Shuman, S. (2022) Fission yeast Duf89 and Duf8901 are cobalt/nickel-dependent phosphatase-pyrophosphatases that act via a covalent aspartyl-phosphate intermediate. J Biol Chem. 10.1016/j.jbc.2022.101851
Sanchez, A. M., Jacewicz, A., and Shuman, S. (2022) Fission yeast Duf89 and Duf8901 are cobalt/nickel-dependent phosphatase-pyrophosphatases that act via a covalent aspartyl-phosphate intermediate. J Biol Chem. 10.1016/j.jbc.2022.101851
Smith, C. R., Kulyk, S., Ahmad, M. Ud Din, Arkhipova, V., Christensen, J. G., Gunn, R. J., Ivetac, A., Ketcham, J. M., Kuehler, J., J Lawson, D., Thomas, N. C., Wang, X., and Marx, M. A. (2022) Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits. RSC Med Chem. 13, 1549-1564
Smith, C. R., Aranda, R., Bobinski, T. P., Briere, D. M., Burns, A. C., Christensen, J. G., Clarine, J., Engstrom, L. D., Gunn, R. J., Ivetac, A., Jean-Baptiste, R., Ketcham, J. M., Kobayashi, M., Kuehler, J., Kulyk, S., J Lawson, D., Moya, K., Olson, P., Rahbaek, L., Thomas, N. C., Wang, X., Waters, L. M., and Marx, M. A. (2022) Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of -Deleted Cancers.. J Med Chem. 10.1021/acs.jmedchem.1c01900
Moghadasi, S. Arad, Esler, M. A., Otsuka, Y., Becker, J. T., Moraes, S. N., Anderson, C. B., Chamakuri, S., Belica, C., Wick, C., Harki, D. A., Young, D. W., Scampavia, L., Spicer, T. P., Shi, K., Aihara, H., Brown, W. L., and Harris, R. S. (2022) Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M/3CL in Living Cells. mBio. 10.1128/mbio.00784-22
Moghadasi, S. Arad, Esler, M. A., Otsuka, Y., Becker, J. T., Moraes, S. N., Anderson, C. B., Chamakuri, S., Belica, C., Wick, C., Harki, D. A., Young, D. W., Scampavia, L., Spicer, T. P., Shi, K., Aihara, H., Brown, W. L., and Harris, R. S. (2022) Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M/3CL in Living Cells. mBio. 10.1128/mbio.00784-22
Moghadasi, S. Arad, Esler, M. A., Otsuka, Y., Becker, J. T., Moraes, S. N., Anderson, C. B., Chamakuri, S., Belica, C., Wick, C., Harki, D. A., Young, D. W., Scampavia, L., Spicer, T. P., Shi, K., Aihara, H., Brown, W. L., and Harris, R. S. (2022) Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M/3CL in Living Cells. mBio. 10.1128/mbio.00784-22
Garcha, H. Kaur, Nawar, N., Sorger, H., Erdogan, F., Aung, M. Myat Khine, Sedighi, A., Manaswiyoungkul, P., Seo, H. - S., Schönefeldt, S., Pölöske, D., Dhe-Paganon, S., Neubauer, H. A., Mustjoki, S. M., Herling, M., de Araujo, E. D., Moriggl, R., and Gunning, P. T. (2022) High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma. Pharmaceuticals (Basel). 10.3390/ph15111321
Garcha, H. Kaur, Nawar, N., Sorger, H., Erdogan, F., Aung, M. Myat Khine, Sedighi, A., Manaswiyoungkul, P., Seo, H. - S., Schönefeldt, S., Pölöske, D., Dhe-Paganon, S., Neubauer, H. A., Mustjoki, S. M., Herling, M., de Araujo, E. D., Moriggl, R., and Gunning, P. T. (2022) High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma. Pharmaceuticals (Basel). 10.3390/ph15111321
Garcha, H. Kaur, Nawar, N., Sorger, H., Erdogan, F., Aung, M. Myat Khine, Sedighi, A., Manaswiyoungkul, P., Seo, H. - S., Schönefeldt, S., Pölöske, D., Dhe-Paganon, S., Neubauer, H. A., Mustjoki, S. M., Herling, M., de Araujo, E. D., Moriggl, R., and Gunning, P. T. (2022) High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma. Pharmaceuticals (Basel). 10.3390/ph15111321
Garcha, H. Kaur, Nawar, N., Sorger, H., Erdogan, F., Aung, M. Myat Khine, Sedighi, A., Manaswiyoungkul, P., Seo, H. - S., Schönefeldt, S., Pölöske, D., Dhe-Paganon, S., Neubauer, H. A., Mustjoki, S. M., Herling, M., de Araujo, E. D., Moriggl, R., and Gunning, P. T. (2022) High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma. Pharmaceuticals (Basel). 10.3390/ph15111321
Cong, A. T. Q., Witter, T. L., and Schellenberg, M. J. (2022) High-efficiency recombinant protein purification using mCherry and YFP nanobody affinity matrices. Protein Sci. 31, e4383
Gnann, A. D., Xia, Y., Soule, J., Barthélemy, C., Mawani, J. S., Musoke, S. Nzikoba, Castellano, B. M., Brignole, E. J., Frueh, D. P., and Dowling, D. P. (2022) High-resolution structures of a siderophore-producing cyclization domain from Yersinia pestis offer a refined proposal of substrate binding. J Biol Chem. 298, 102454
Hickerson, B. T., Daniels-Wells, T. R., Payes, C., Clark, L. E., Candelaria, P. V., Bailey, K. W., Sefing, E. J., Zink, S., Ziegenbein, J., Abraham, J., Helguera, G., Penichet, M. L., and Gowen, B. B. (2022) Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections. Nat Commun. 13, 558
Goodman, K. Marie, Katsamba, P. S., Rubinstein, R., Ahlsen, G., Bahna, F., Mannepalli, S., Dan, H., Sampogna, R. V., Shapiro, L., and Honig, B. (2022) How clustered protocadherin binding specificity is tuned for neuronal self-/nonself-recognition. Elife. 10.7554/eLife.72416
Goodman, K. Marie, Katsamba, P. S., Rubinstein, R., Ahlsen, G., Bahna, F., Mannepalli, S., Dan, H., Sampogna, R. V., Shapiro, L., and Honig, B. (2022) How clustered protocadherin binding specificity is tuned for neuronal self-/nonself-recognition. Elife. 10.7554/eLife.72416
Sharma, S., Yang, J., Doamekpor, S. K., Grudizen-Nogalska, E., Tong, L., and Kiledjian, M. (2022) Identification of a novel deFADding activity in human, yeast and bacterial 5' to 3' exoribonucleases. Nucleic Acids Res. 50, 8807-8817
Bubenik, M., Mader, P., Mochirian, P., Vallée, F., Clark, J., Truchon, J. - F., Perryman, A. L., Pau, V., Kurinov, I., Zahn, K. E., Leclaire, M. - E., Papp, R., Mathieu, M. - C., Hamel, M., Duffy, N. M., Godbout, C., Casas-Selves, M., Falgueyret, J. - P., Baruah, P. S., Nicolas, O., Stocco, R., Poirier, H., Martino, G., Fortin, A. Bonneau, Roulston, A., Chefson, A., Dorich, S., St-Onge, M., Patel, P., Pellerin, C., Ciblat, S., Pinter, T., Barabé, F., Bakkouri, M. El, Parikh, P., Gervais, C., Sfeir, A., Mamane, Y., Morris, S. J., W Black, C., Sicheri, F., and Gallant, M. (2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998
Bubenik, M., Mader, P., Mochirian, P., Vallée, F., Clark, J., Truchon, J. - F., Perryman, A. L., Pau, V., Kurinov, I., Zahn, K. E., Leclaire, M. - E., Papp, R., Mathieu, M. - C., Hamel, M., Duffy, N. M., Godbout, C., Casas-Selves, M., Falgueyret, J. - P., Baruah, P. S., Nicolas, O., Stocco, R., Poirier, H., Martino, G., Fortin, A. Bonneau, Roulston, A., Chefson, A., Dorich, S., St-Onge, M., Patel, P., Pellerin, C., Ciblat, S., Pinter, T., Barabé, F., Bakkouri, M. El, Parikh, P., Gervais, C., Sfeir, A., Mamane, Y., Morris, S. J., W Black, C., Sicheri, F., and Gallant, M. (2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998
Bubenik, M., Mader, P., Mochirian, P., Vallée, F., Clark, J., Truchon, J. - F., Perryman, A. L., Pau, V., Kurinov, I., Zahn, K. E., Leclaire, M. - E., Papp, R., Mathieu, M. - C., Hamel, M., Duffy, N. M., Godbout, C., Casas-Selves, M., Falgueyret, J. - P., Baruah, P. S., Nicolas, O., Stocco, R., Poirier, H., Martino, G., Fortin, A. Bonneau, Roulston, A., Chefson, A., Dorich, S., St-Onge, M., Patel, P., Pellerin, C., Ciblat, S., Pinter, T., Barabé, F., Bakkouri, M. El, Parikh, P., Gervais, C., Sfeir, A., Mamane, Y., Morris, S. J., W Black, C., Sicheri, F., and Gallant, M. (2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998
Bubenik, M., Mader, P., Mochirian, P., Vallée, F., Clark, J., Truchon, J. - F., Perryman, A. L., Pau, V., Kurinov, I., Zahn, K. E., Leclaire, M. - E., Papp, R., Mathieu, M. - C., Hamel, M., Duffy, N. M., Godbout, C., Casas-Selves, M., Falgueyret, J. - P., Baruah, P. S., Nicolas, O., Stocco, R., Poirier, H., Martino, G., Fortin, A. Bonneau, Roulston, A., Chefson, A., Dorich, S., St-Onge, M., Patel, P., Pellerin, C., Ciblat, S., Pinter, T., Barabé, F., Bakkouri, M. El, Parikh, P., Gervais, C., Sfeir, A., Mamane, Y., Morris, S. J., W Black, C., Sicheri, F., and Gallant, M. (2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998
Zeyen, P., Zeyn, Y., Herp, D., Mahmoudi, F., Yesiloglu, T. Z., Erdmann, F., Schmidt, M., Robaa, D., Romier, C., Ridinger, J., Herbst-Gervasoni, C. J., Christianson, D. W., Oehme, I., Jung, M., Krämer, O. H., and Sippl, W. (2022) Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells. Eur J Med Chem. 234, 114272
Zeyen, P., Zeyn, Y., Herp, D., Mahmoudi, F., Yesiloglu, T. Z., Erdmann, F., Schmidt, M., Robaa, D., Romier, C., Ridinger, J., Herbst-Gervasoni, C. J., Christianson, D. W., Oehme, I., Jung, M., Krämer, O. H., and Sippl, W. (2022) Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells. Eur J Med Chem. 234, 114272
Murray, K. A., Hughes, M. P., Hu, C. J., Sawaya, M. R., Salwinski, L., Pan, H., French, S. W., Seidler, P. M., and Eisenberg, D. S. (2022) Identifying amyloid-related diseases by mapping mutations in low-complexity protein domains to pathologies. Nat Struct Mol Biol. 29, 529-536
Murray, K. A., Hughes, M. P., Hu, C. J., Sawaya, M. R., Salwinski, L., Pan, H., French, S. W., Seidler, P. M., and Eisenberg, D. S. (2022) Identifying amyloid-related diseases by mapping mutations in low-complexity protein domains to pathologies. Nat Struct Mol Biol. 29, 529-536

Pages